Search Results for: GNPX

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its Board of Directors. The new appointments, which include Brent Longnecker, CEO of Longnecker & Associates, Jose A. Moreno Toscano, CEO of LFB USA Inc, and William R. … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Strategic Board Appointments of Three Biotechnology and Healthcare Industry Leaders”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Catherine M. Vaczy as executive vice president and chief strategy officer and Michael T. Redman as executive vice president and chief operating officer. These appointments follow on the heels of Genprex’s Fast … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Expands Leadership Team with Appointment of Accomplished Life Science Executives”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced that Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy. According to the update, Dr. Gittes joined … Continue reading “QualityStocksNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Lead Researcher Behind its Diabetes Gene Therapy Featured in New Video Interview”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, this morning announced that the company’s chairman and chief executive officer Rodney Varner will be leading a presentation and answering questions from investors at the third annual LD Micro Virtual Conference. The company’s presentation is scheduled to … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) CEO Presenting at the 2020 LD Micro Virtual Conference”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced that it will present at the third annual LD Micro Virtual Conference at 1:40 p.m. EST on Wednesday, March 4. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and answer … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Present at the Third Annual LD Micro Virtual Conference”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, on Wednesday announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 5,000,000 shares of common stock, par value $0.001 per share, at an offering price of … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $17,500,000 Common Stock Offering At-The-Market”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced its entry into an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh for Potentially Curative Gene Therapy Candidate for Diabetes”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its February 4, 2020 receipt of notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the company has regained compliance with the minimum bid price requirement under Nasdaq Listing … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Meets Nasdaq Minimum Bid Price Requirement, Regains Compliance”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provided a clinical update and focus for its Oncoprex(TM) immunogene therapy program for 2020. According to the update, Genprex will prioritize the development of Oncoprex in combination with osimertinib for the … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Focus Clinical Efforts on Oncoprex(TM) in Combination with Osimertinib for Treatment of Non-Small Cell Lung Cancer”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that it will present at the Noble Capital Markets 16th Annual Investor Conference. Genprex’s presentation is scheduled to take place at 1:30 p.m. EST on Monday, February 17, 2020, at … Continue reading “QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at NobleCon16 Investor Conference”